Detalhe da pesquisa
1.
Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain.
Mol Ther
; 32(2): 503-526, 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38155568
2.
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
Blood
; 140(5): 451-463, 2022 08 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35605184
3.
A novel approach for characterization of KSHV-associated multicentric Castleman disease from effusions.
Br J Haematol
; 200(4): 462-475, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36264007
4.
Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Blood
; 136(1): 93-105, 2020 07 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32202637
5.
Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
Blood
; 131(21): 2357-2366, 2018 05 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-29483101
6.
Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvement.
Pediatr Blood Cancer
; 67(4): e28149, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31981407
7.
Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia.
Blood
; 129(11): 1469-1479, 2017 03 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-28049639
8.
'A novel approach for characterisation of KSHV-associated multicentric Castleman disease from effusions': Response.
Br J Haematol
; 201(2): 360-363, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36794595
9.
Treatment of HIV-associated primary CNS lymphoma with antiretroviral therapy, rituximab, and high-dose methotrexate.
Blood
; 136(19): 2229-2232, 2020 11 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32609814
10.
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Blood
; 121(7): 1165-74, 2013 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-23243285
11.
A phase II study of ibrutinib and short-course fludarabine in previously untreated patients with chronic lymphocytic leukemia.
Am J Hematol
; 95(11): E310-E313, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32808680
12.
Characterization of CD22 expression in acute lymphoblastic leukemia.
Pediatr Blood Cancer
; 62(6): 964-9, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25728039
13.
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma.
Haematologica
; 103(5): e215-e218, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29419431
14.
Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease.
Oncoimmunology
; 12(1): 2163784, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36632565
15.
Circulating CD22+/CD19-/CD24- progenitors and CD22+/CD19+/CD24- mature B cells: Diagnostic pitfalls for minimal residual disease detection in B-lymphoblastic leukemia.
Cytometry B Clin Cytom
; 104(4): 294-303, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433814
16.
COVID-19 in patients with classic and variant hairy cell leukemia.
Blood Adv
; 7(23): 7161-7168, 2023 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37729613
17.
Chimeric Antigen Receptor T Cells as Salvage Therapy for Post-Chimeric Antigen Receptor T Cell Failure.
Transplant Cell Ther
; 29(9): 574.e1-574.e10, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37394115
18.
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells.
Blood Adv
; 7(4): 575-585, 2023 02 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-35482927
19.
Acute and delayed cytopenias following CAR T-cell therapy: an investigation of risk factors and mechanisms.
Leuk Lymphoma
; 63(8): 1849-1860, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35389319
20.
Phase II Trial of Inotuzumab Ozogamicin in Children and Adolescents With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Children's Oncology Group Protocol AALL1621.
J Clin Oncol
; 40(9): 956-967, 2022 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007127